Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2013-10-20 AGM Information
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Proxy Form 2 pages 341.9KB
AGM Information Classification · 100% confidence The document is a proxy form for an Annual General Meeting (AGM) of Allied Healthcare Group Ltd. It includes instructions on how to vote, appoint proxies, and details about the meeting date and location. It also lists resolutions to be voted on, such as adoption of reports, re-election of directors, and share issues. There is no financial data or report content, only voting instructions and proxy appointment details. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms. The document length is 8823 characters, which is consistent with a detailed proxy form rather than a brief announcement or a full report. Therefore, the correct classification is AGM Information (AGM-R).
2013-10-20 English
Full Annual Report to shareholders 80 pages 5.2MB
Regulatory Filings
2013-10-20 English
Allied Herpes Phase I Trial progress update 2 pages 271.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing an update on the progress of a Phase I clinical trial for a therapeutic vaccine targeting Herpes simplex virus 2 (HSV-2). It includes details about the trial cohorts, dosing progress, safety observations, and the technology behind the vaccine. There are no financial statements, regulatory certifications, voting results, or management changes discussed. The content is focused on clinical trial progress and company R&D updates rather than financial or governance reporting. This type of announcement fits best under the category of a general regulatory announcement or update to the market, which aligns with the Regulatory Filings (RNS) category. The document length is moderate and it is not a report publication announcement or a full report itself.
2013-10-16 English
8 Surgeons get approval to use CardioCel in adult patients 2 pages 198.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated October 8, 2013, about Allied Healthcare Group receiving approval for surgeons to use their product CardioCel in adult patients. It discusses regulatory approvals, market potential, and product details. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about product approval and market expansion, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best as a general regulatory announcement about company developments, which falls under Regulatory Filings (RNS).
2013-10-07 English
Appendix 3B - Exercise of Options 14 pages 694.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form submitted to the Australian Stock Exchange (ASX), which is a standard form used to announce the allotment of new securities, specifically the exercise of options and issuance of ordinary shares. It includes detailed information about the securities issued, exercise price, shareholder approvals, and compliance with ASX listing rules. The document is not a financial report, earnings release, or management discussion but a regulatory announcement about a capital change event. This fits the category of Share Issue/Capital Change announcements, as it details the issuance of new shares following option exercises and the related compliance disclosures.
2013-10-07 English
Dispatch of Offer Document 1 page 199.5KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement (734 characters) about the dispatch of an Offer Document related to a pro-rata non-renounceable rights issue. It does not contain the actual Offer Document or detailed financial data but merely informs that the Offer Document has been sent out. This fits the category of a Capital/Financing Update (CAP) because it relates to a rights issue, which is a capital raising activity. The document is not a full report or detailed financial statement, so it is not classified as an Annual Report or Interim Report. It is also not a Report Publication Announcement since it does not mention the publication or availability of a report but the dispatch of an offer document for a rights issue. Therefore, the best classification is CAP with high confidence.
2013-10-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.